A Phase 3 interventional study of Clevudine and Adefovir in Chronic Hepatitis and Hepatitis B, sponsored by Pharmasset. Terminated at 119 sites in 11 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2009-04-27.
Sponsored by Pharmasset · Phase 3, Interventional, and Treatment
The objectives of this study are to compare in nucleoside treatment-naïve subjects, the efficacy and safety of clevudine 30 mg once daily versus adefovir 10 mg once daily, each as monotherapy, for 48 weeks, 72 weeks, and 96 weeks.
2,709 studies on the registry are indexed under Hepatitis A; 142 are open to participants now.
Browse Hepatitis A studies →Pharmasset is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Showing the first 100 of 119 sites across 11 countries.
This study is terminated, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pharmasset